In contrast, mutations in signaling genes, mainly RAS pathway (30%) and JAK2 (10%) mutations, are associated with MP-CMML, characterized by leukocytosis, splenomegaly, constitutional symptoms, higher number of mutations and reduced survival. The gene discussed is JAK2; the disease is chronic myelomonocytic leukemia.